Torcetrapib 02895 Hydrochloride Smiles: C[C@H]1C=CC=CCCC=CC=CC=CC=CC(CC2O[C@](O)(CC(O)C(O)CCC(O)CC(O)CC(O)CC(=O)O[C@@H](C)[C@H](C)[C@@H]1O)CC(O)C2C(O)=O)O[C@H]1O[C@H](C)[C@@H](O)[C@H](N)[C@@H]1O |t:2

Smiles: C[C@H]1C=CC=CCCC=CC=CC=CC=CC(CC2O[C@](O)(CC(O)C(O)CCC(O)CC(O)CC(O)CC(=O)O[C@@H](C)[C@H](C)[C@@H]1O)CC(O)C2C(O)=O)O[C@H]1O[C@H](C)[C@@H](O)[C@H](N)[C@@H]1O |t:2

resulting in the accumulation of single- or double-strand DNA breaks

including T315I

a mitotic Kinesin Eg5 inhibitor

Formula: C18H22F2N4O

Torcetrapib 02895 Hydrochloride Smiles: C[C@H]1C=CC=CCCC=CC=CC=CC=CC(CC2O[C@](O)(CC(O)C(O)CCC(O)CC(O)CC(O)CC(=O)O[C@@H](C)[C@H](C)[C@@H]1O)CC(O)C2C(O)=O)O[C@H]1O[C@H](C)[C@@H](O)[C@H](N)[C@@H]1O |t:2Torcetrapib, also known as CP 529,414 was a drug being developed to treat hypercholesterolemia (elevated cholesterol levels) and prevent cardiovascular disease. Its development was halted in 2006 when phase III studies showed excessive all cause mortality in the treatment group receiving a combination of atorvastatin (Lipitor) and torcetrapib. Torcetrapib acts (as a CETP inhibitor) by inhibiting cholesterylester transfer protein (CETP), which normally